Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries
-- Significant portion of alliance opportunity will remain unchanged; some countries will transition to exclusive promotion in 2015
The changes will be implemented starting
The scope of the alliance will remain unchanged in the following 17 countries:
Under a revised agreement, Boehringer Ingelheim and Lilly will exclusively commercialize the respective molecules they brought to the alliance in all other countries under revised financial terms that will include an upfront payment and ongoing payments paid to Lilly in lieu of commission payments in those markets. Lilly plans to communicate the impact to its 2014 financial guidance in its third quarter Form 10-Q report to the
"Lilly and Boehringer Ingelheim have a highly successful alliance," said
To date, three new treatments for diabetes have been launched by the alliance: Trajenta® (linagliptin), Jardiance® (empagliflozin), and Jentadueto® (linagliptin/metformin HCI). Additionally, the alliance's new insulin glargine product has been tentatively approved in the U.S. and approved in
"As our alliance continues to evolve, and with more medicines receiving approval by regulators, we have determined that enhancements are needed to reduce operational complexities in certain countries around the world," said Dr
Boehringer Ingelheim and
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim,
Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "
In 2013, Boehringer Ingelheim achieved net sales of about
For more information please visit www.boehringer-ingelheim.com.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.
Phone: +1 (317) 432-5195
Phone: +49 (6132) 77-7051
News Provided by Acquire Media